Holocene Advisors
GPCR icon

Holocene Advisors’s Structure Therapeutics GPCR Stock Holding History

Holocene Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-159,009
Closed -$7.66M – 891
2026
Q1 		$7.66M Buy
+159,009
New +$10.9M 0.02% 340
2023
Q4 		– Sell
-281,291
Closed -$14.2M – 752
2023
Q3 		$14.2M Buy
+281,291
New +$9.07M 0.06% 232

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Holocene Advisors's GPCR Position: Q2 2026 in Review

Holocene Advisors sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 159,009 shares — an estimated $7.66M sold.

Holocene Advisors first reported a position in GPCR in Q3 2023 and held it in 2 quarters. The position peaked at $14.2M in Q3 2023. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Holocene Advisors reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Holocene Advisors sold 159,009 Structure Therapeutics shares in Q2 2026, an estimated $7.66M.
  • Holocene Advisors first reported a position in Structure Therapeutics in Q3 2023 and held it in 2 quarters.
  • Holocene Advisors's Structure Therapeutics position peaked at $14.2M in Q3 2023.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.